Jennifer Champoux
Chief Operating Officer at MONTE ROSA THERAPEUTICS, INC.
Net worth: 711 428 $ as of 2024-06-29
Profile
Jennifer Champoux currently works at Monte Rosa Therapeutics, Inc., as Chief Operating Officer from 2024.
Ms. Champoux also formerly worked at H3 Biomedicine, Inc., as Executive Director-Operations.
Ms. Champoux received her graduate degree from Indiana University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
DIGITAL TURBINE, INC.
0.42% | 2024-06-02 | 428,571 ( 0.42% ) | 711 428 $ | 2024-06-29 |
2024-06-02 | 0 ( -.--% ) | - $ | 2024-06-29 |
Jennifer Champoux active positions
Companies | Position | Start |
---|---|---|
MONTE ROSA THERAPEUTICS, INC. | Chief Operating Officer | 2021-02-28 |
Former positions of Jennifer Champoux
Companies | Position | End |
---|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Training of Jennifer Champoux
Indiana University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- Jennifer Champoux